Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

BEWARE: ENDV CONTINUES LIES ABOUT ITS DEVELOPMENT

As we have seen, ENDV Management has recently put out a new PR: Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies

In this PR ENDV states:

Endonovo has received an overwhelmingly positive response from clinical researchers regarding the potential effectiveness of its SofPulse® Pulsed Electro Magnetic Field (PEMF) technology in treating TBI. SofPulse® has garnered significant interest from neuroscientists, orthopedic neurologists and cognitive researchers at some of the most prestigious institutions in the world, including Harvard University, Boston’s Spaulding Rehabilitation Hospital and Stanford University.

ENDV makes deceiving statements about its PEMF product such as:

In past studies, SofPulse® PEMF therapy has demonstrated effectiveness in treating TBI and PCS. The therapy has been found to promote cellular repair, improve blood flow and reduce inflammation in the brain, which is a hallmark of TBI that can lead to severe symptoms such as tissue breakdown, swelling and cell death.

There are no clinical trials demonstrating effectiveness in treating TBI and Post-Concussion Syndrome (PCS) in humans, all I see are studies in mice. If ENDV did have human trials demonstrating PEMF being effective in treating TBI then it would be in a position to obtain a FDA 510k Clearance for its product. However, it is purposefully misrepresenting its product, its studies and results to garner attention for the sole purpose of increasing liquidity.

Furthermore, ENDV has a bad habit of only putting out PR's to announce good news or to pump its stock, but conveniently refrains from putting out press releases and 8K's to inform its shareholders about negative events, such as losing patent lawsuits, executives leaving, and CLINICAL STUDIES being shut down or simply abandoned.

For the long time ENDV followers and shareholders, ENDV already put out PR's a few years ago about conducting clinical trials to evaluate its PEMF device in treating TBI:

Endonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New Mexico

Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical™ Therapy

ENDV has never updated shareholders regarding this clinical trial, but as we have found out via our own due diligence, the study's lead investigator started his own company and the status of the clinical trial has never been updated:

NSI Pulsed Electromagnetic Field (PEMF) Biomarker Study

To date we still have no clue what is happening with this study, but what we do know is that it is not active. Whether it simply did not work, ENDV couldn't fund it, or the lead investigator simply left for whatever reason we will never know because ENDV refuses to be transparent. It does not put out PRs to update, it does not file 8K's to let us know it was shut down and it will not address it in its "shareholder updates" and self-selected Q/A's.

ENDV has a clear history of using Press Releases as stock promotions to create liquidity for its dilutive financings which means that it never puts out actual news regarding its actual progress. Seems like ENDV has now resorted to recycling PR's to keep the stock trading.

BUYER BEWARE